Effects of a Chronic Low Carbohydrate High Fat Diet on Markers of Cholesterol and Lipoprotein Metabolism in Elite Level Ultra-endurance Male Runners by Creighton, Brent C
University of Connecticut
OpenCommons@UConn
Doctoral Dissertations University of Connecticut Graduate School
6-26-2015
Effects of a Chronic Low Carbohydrate High Fat
Diet on Markers of Cholesterol and Lipoprotein
Metabolism in Elite Level Ultra-endurance Male
Runners
Brent C. Creighton
Unniversity of Connecticut, BrentCreighton@gmail.com
Follow this and additional works at: https://opencommons.uconn.edu/dissertations
Recommended Citation
Creighton, Brent C., "Effects of a Chronic Low Carbohydrate High Fat Diet on Markers of Cholesterol and Lipoprotein Metabolism in
Elite Level Ultra-endurance Male Runners" (2015). Doctoral Dissertations. 893.
https://opencommons.uconn.edu/dissertations/893
Effects of a Chronic Low Carbohydrate High Fat Diet on Markers of Cholesterol and 
Lipoprotein Metabolism in Elite Level Ultra-endurance Male Runners 
Brent C. Creighton, P.hD. 
University of Connecticut, 2015 
 
The long-term safety of low carbohydrate high fat diets (LCHFD) continues to remain 
in question. Previous research has shown marked variability in the cholesterol 
response among those who adopt a LCHFD, raising concern, as elevated cholesterol 
is associated with increased risk for cardiovascular disease. More in-depth analyses 
are necessary to determine if elevated cholesterol associated with chronic 
consumption of a LCHFD increases atherogenic risk. Assessment of lipoprotein 
subfractions and noncholesterol sterol biomarkers provide a greater ability to quantify 
atherogenic risk. Twenty highly trained male ultra marathoners habitually consumed 
either a traditional high-carbohydrate HC: n=10, %carbohydrate:protein:fat = 
57:15:27) diet or a low-carbohydrate (LC; n=10, 10:19:70) diet for an average of 20 
mo (range 9 to 36 mo). Serum total (TC), low-density lipoprotein (LDL-C), and high-
density lipoprotein (HDL-C) cholesterol were all greater in the LCHF group (TC: 277.7 
± 50.6 vs 168.7 ± 24.4 mg/dL; P=0.0000, LDL-C: 161.3 ± 37.4 vs 88.1 ± 13.7 mg/dL; 
P=0.0000, HDL-C: 102.3 ± 26.2 vs 63.9 ± 18.0 mg/dL; P=0.0007). Noncholesterol 
sterol biomarkers were used to calculate fractional cholesterol balance and was not 
significantly different between groups (0.60 ± 0.16 vs 0.66 ± 0.22). Men in the LCHF 
group presented less atherogenic lipoprotein profiles. Mean VLDL particle size was 
significantly reduced in the LC group (38.2 ± 4.1 vs 43.65 ± 1.7 nm; P=0.0022), while 
mean LDL (21.5 ± 0.34 vs 20.1 ± 0.35 nm; P=0.0102) and HDL (10.2 ± 0.47 vs 9.5 ± 
0.47 nm; P=0.0053) particle size were greater. Total LDL particle count was 
significantly greater in the LCHF group (1363 ± 343 vs 893 ± 196 nmol/L; P=0.0021). 
Although not statistically different (P=0.0021), the LCHF group had 126% less small 
LDL particles (160.6 ± 134.8 vs 363.0 ± 245.2 nmol/L; P=0.1013). Total HDL particles 
were not significantly different between groups (P=0.1369). HDL particle distribution 
was comprised of significantly more atheroprotective large particles (14.8 ± 4.4 vs 8.1 
± 3.4 nmol/L; P=0.0013). These results provide further evidence that compared to 
HCD, habitual LCHFDs, irrespective of high circulating cholesterol, due not 
significantly alter fractional cholesterol balance and shift the lipoprotein profile 
towards a more atheroprotective state. 
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Chapter 1 
Review of Literature 
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Current Perspective 
Low carbohydrate high fat diets (LCHFD) continue to be a therapeutic means 
for improving metabolic and atherogenic risk factors and although no official definition 
of LCHF diets exist, arbitrary levels have been defined as less than 50 grams of 
carbohydrates per day or less than 10% of total energy intake1. Many professional 
organizations2,3 continue to discourage LCHFD as long-term health outcomes remain 
in question. Though few, recent long-term studies, greater than six months in 
duration, have shown remarkably promising results for up to twelve months following 
a LCHFD4-7. These longitudinal studies, however, measured only mass cholesterol 
levels and were conducted with overweight, diabetic subjects where weight loss was 
a contributing factor. What remains to be seen, are the implications a LCHFD may 
have on cholesterol levels and cardiovascular risk when maintained for chronic 
periods of time (6 < months) in healthy normolipidemic individuals.  
Published studies investigating the effects of LCHF diets on metabolic health 
in healthy, normolipidemic individuals, have shown variable responses in circulating 
cholesterol levels [total (TC) and low-density lipoprotein cholesterol (LDL-C)] not 
attributable to weight loss8-13. Numerous cross sectional and prospective 
investigations have illustrated that LCHF diets improve cardiometabolic risk factors14. 
Many if not all of these studies report data on subjects who followed a LCHF diet for 
no greater than 4-12 weeks. To our knowledge, no study to date has assessed 
measures of cardiovascular disease (CVD) risk and cholesterol balance in healthy, 
fit, normolipdemic men, who have followed a LCHFD for longer than six months.  
  3 
Cholesterol 
The importance of cholesterol in the human body is unquestionable as 
disorders in synthesis result in a myriad of adverse syndromes15. Still, elevated levels 
of total serum cholesterol and LDL-C are associated with increased risk of 
cardiovascular diseases (CVD) such as atherosclerosis, myocardial infraction, and 
stroke16,17. Current international guidelines16,17 continue to weigh heavily on 
cholesterol markers for the evaluation of CVD risk. It is reasonable to suggest that 
total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density 
lipoprotein cholesterol (HDL-C) metrics are well known by the lay public, but not well 
understood. Published guidelines and practitioners advise patients to keep TC below 
200mg/dL, LDL-C under 130mg/dL, and HDL-C over 40mg/dL16 depending on ones 
potential risk for CVD. Arguably, the question needing to be asked is whether or not 
these values and subsequent guidelines pertaining to serum cholesterol really help 
predict CVD risk. Although still a minority, a growing body of researchers and 
practitioners are beginning to argue that measuring circulating cholesterol levels have 
no relevance for accurately predicting CVD.  
Circulating cholesterol levels are themselves highly variable as are indirect 
surrogate markers, particularly in response to dietary changes in cholesterol18 such 
as can occur on a LCHFD. Cholesterol levels following increased dietary 
consumption may decrease, increase, or stay the same. Of particular concern are 
variations or increases in LDL-C following cholesterol feeding, which have similarly 
been shown under metabolic ward conditions by Sehayek et al 199819.  
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It is well established that endogenous cholesterol metabolism is inversely 
regulated. Reduced intestinal absorption of cholesterol causes an up-regulation of 
cholesterol synthesis, where as increased intestinal absorption causes the liver to 
suppress cholesterol synthesis20. Various human studies have suggested that an 
individuals ability to down-regulate endogenous cholesterol synthesis in response to 
increased cholesterol intake helps limit their plasma lipoprotein responsiveness21,22. 
Animal data helps provide further evidence. Species that tolerate and adapt more 
efficiently to an increased dietary cholesterol load include those, which have an 
innately greater rate of hepatic cholesterol synthesis (rats, mice, squirrel monkeys)23. 
These species down regulate synthesis more readily and are less responsive to 
dietary changes of cholesterol. Importantly, these species, which are frequently used 
in experiments for studying metabolism, may not translate into suitable models for 
human comparison. Humans have lower rates of hepatic cholesterol synthesis and 
so are more responsive to dietary changes in cholesterol. Endogenous cholesterol 
consumed in the diet mixes with biliary cholesterol in the intestines. Overall, most 
cholesterol within the intestinal lumen is actually derived from endogenous sources 
(bile), with dietary cholesterol contributing very little. Although highly variable, the 
average American consumes approximately 0.4g of cholesterol per day24. Ultimately, 
the amount of cholesterol absorbed equals the amount lost (i.e., the body 
synthesizes an amount approximately equal to the amount it absorbs24.  
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Surrogate Markers of Cholesterol Synthesis and Absorption 
Serum cholesterol concentrations are derived from two sources; endogenous 
cholesterol from hepatic and extra-hepatic synthesis, and exogenous cholesterol 
derived from intestinal absorption of dietary and biliary cholesterol23. Absolute 
quantification of cholesterol synthesis is difficult and time consuming, requiring 
measures of cholesterol output (fecal measurements and bile acids) and dietary 
intake to quantify total sterol balance [Output – Intake = Synthesis]. In response to 
these methodological difficulties, more recent, less arduous approaches to quantify 
cholesterol balance have been developed. These measurements vary but can 
include assessment of serum non-cholesterol sterols, synthesis markers (lathosterol 
and desmosterol), and absorption markers (beta-sitosterol, campesterol, and 
cholestanol). These sterol-based biomarkers are currently used primarily to assess 
the cause of hypercholesterolemia and can help to determine therapy selection. In 
addition, noncholesterol sterols can be extremely useful in determining and better 
understanding disease states25.  
The cholesterol balance score is calculated by taking the ratio of cholesterol 
synthesis or production measurements and dividing it by cholesterol absorption 
measurements. Pre-cholesterol sterols leak into lipoproteins at a rate proportional to 
that of their formation in the cholesterol synthetic pathway, thus is the rational for 
using them as indicators of synthesis26. In addition, all sterols including plant sterols 
are transported in lipoproteins, predominantly the LDL and HDL subfractions27. 
Plasma non-cholesterol sterols are frequently reported as a ratio to cholesterol in 
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order to normalize the differences caused by variable levels of lipoproteins that 
transport cholesterol and the sterols28. 
 
Cholesterol Synthesis Pathway 
The process of cholesterol synthesis is complex, highly regulated, and 
controlled by a myriad of factors. Zoosterol’s or cholesterol that is synthesized in 
mammalian cells originates from acetate. Figure 1 illustrates an overly simplified 
version of the important steps in the cholesterol synthesis pathway29.  
 
Figure 1: Cholesterol synthesis pathways 
 
As shown above, acetate is converted to 3-hydroxy-3-methyl-glutaryl-CoA (HMG-
CoA) by HMG-CoA synthase and then to mevalonate by HMG-CoA reductase. This 
conversion step, HMG-CoA reductase, is where statin drugs are utilized to stop 
cholesterol synthesis. Mevalonate is converted to squalene and finally to lanosterol. 
The final stages of cholesterol synthesis shuttle lanosterol through two distinct 
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synthetic pathways, the Kandutsch-Rusell30 pathway and the Bloch pathway. 
Accounting for nearly 80% of endogenous cholesterol synthesis, the Kandutsch-
Rusell pathway converts lanosterol first to lathosterol, then to 7-dehydrochoolesterol, 
and finally cholesterol. Conversely, the Bloch pathway accounts for the remaining 
20%, converting desmosterol to cholesterol. Although yet to be fully mapped out, it is 
thought that both pathways are likely independently regulated and share many of the 
same enzyme pathways15. Intermediary sterols, squalene, lathosterol, desmosterol 
can and are used as biomarkers to evaluate cholesterol synthesis31,32. Elevated 
concentrations of these markers indicate increased endogenous production. The 
value of measuring cholesterol precursors lies with the assumption that serum they 
leak into plasma lipoproteins at a rate relative to that of their formation in the 
synthetic pathway26. 
Lathosterol and desmosterol are two of the major cholesterol precursors which 
can be used as markers of hepatic synthesis33,34. Both precholesterol sterols 
maintain very low circulating levels while transported and distributed in a very similar 
manner to that of cholesterol. Inherited metabolic diseases or abnormal clinical 
conditions (fatty liver disease or insulin résistance) may cause an elevation in either 
of these sterols35. In particular, cholesterol precursors show a high degree of 
association with fecal cholesterol synthesis, making them a strong alternative option.  
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Mechanism of Cholesterol Absorption 
The manner by which cholesterol is absorbed from the gut lumen is a tightly 
regulated process which has been studied extensively36,37. Intestinal cholesterol 
originates from dietary absorption, the hepatobilary system, and intestinal epithelial 
slothing, contributing roughly 2000mg/day37.  The standard western diet on average 
contributes about 300-500 mg of thus total through intestinal absorption. Absorbed 
cholesterol is transported in micelles, which form in conjunction with other newly 
absorbed lipids (phospholipids and monoglycerides) and the help of bile salts. 
Micelles then facilitate transport of cholesterol to the brush border of the small 
intestines where cholesterol is removed and unesterified cholesterol passes through 
to the enterocytes by way of the Niemann-Pick C1-like (NPC1) transporter. Once 
absorbed, cholesterol is then esterified by acyl-CoA cholesterol acyltrasnferase 
(ACAT). Efflux from the enterocytes is mediated by intestinal ATP-binding cassette 
transporters (ABC) G5 and G8 proteins, which are highly sensitive to plant sterols. 
Genetic variances in this protein can result in hyperabsorption of cholesterol38 and 
considering an estimated 5% of plant sterols are absorbed from the gut39, elevated 
levels can be considered toxic.   
Once absorbed and esterified, cholesterol is then packaged and transported to 
the liver in chylomicrons, where newly absorbed cholesterol has a direct impact on 
lipoprotein production and removal pathways23,40. Between individuals, differences in 
enzyme kinetics (Km and/or Vmax) related to cholesterol absorption is a likely factor 
influencing cholesterol flux as is Apo E genotype41; this has not been found true in all 
cases19. Overall, the precise mechanism regulating cholesterol homeostasis has yet 
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to be fully mapped out. Still, effects of circadian rhythm, body weight, and diet on 
cholesterol response clearly demonstrate the presence of genetically determined 
differences that control a person’s cholesterol responsiveness19,42.  
The assessment of hypercholesterolemia can be conducted using plant sterol 
biomarkers β-sitosterol and campesterol, the major phytosterols present in human 
serum ad tissues. Phytosterols serve a supporting role in plant membrane function, 
not unlike cholesterol in animals but serve no function in human physiology. Naturally 
more hydrophobic than animal sterols, plant sterols consumed in the diet 
endogenously inhibit cholesterol absorption by competing for incorporation into 
micelles and transport through the NPC1 transporter43. Ratios of serum phytosterols 
to cholesterol largely depend on absorption efficiency, biliary secretion, and the 
amount consumed in the diet. Quantification of β-sitosterol and campesterol, when 
normalized to cholesterol, act as surrogates for evaluating cholesterol absorption 
because humans do not produce phytosterols44.  
Although less commonly used, cholestanol can also be used to assess 
absorption rates. Cholestanol is a synthesized metabolite of cholesterol which exists 
ubiquitously throughout the body at a concentration of roughly 1/500 to 1/800 of 
cholesterol45. Similar to other noncholesterol sterols, accumulation of cholestanol 
results in adverse pathological conditions. Similar to plant sterol absorption, elevated 
levels of cholestanol in the circulation is indicative of increased absorption at the gut. 
 
  10 
Considerations for Lipid Assessment 
In low carbohydrate studies, weight loss is frequently both a desired outcome 
as well as a useful tool for subject recruitment. Still, caution is advised when 
interpreting changes in lipids (cholesterol and triglycerides). A meta-analysis 
conducted by Dattilo and Kris-Etherton46 concluded that for every kilogram of body 
weight lost, there is an associated 0.015 mmol/L reduction in serum triacylglycerols. 
Furthermore, whether subjects are actively losing weight or weight stable has been 
shown to have an effect on both the magnitude and direction of cholesterol levels47 
making weight loss, independent of diet, a potential confounding factor when 
evaluating lipid levels in dietary studies. In addition, weight loss itself likely plays a 
large role in influencing the lipoprotein profile. Wood et al.14 illustrated that a LCHFD 
in conjunction with weight loss helped improve lipoprotein subclasses. Similarly, 
Katzel et al.48 showed weight loss to aid in the favorable redistribution of lipoprotein 
subclasses. Thus, it is impetrative to consider weight loss when assessing changes 
in lipids. 
  An additional consideration when evaluating changes in lipids is whether or 
not obese and normal weight individuals respond differently to dietary cholesterol. 
The mechanism of dietary cholesterol has been well established49,50. Increased 
consumption of dietary cholesterol contributes to the already recycled biliary 
cholesterol pool and increases the volume of cholesterol entering the liver. Upon 
exposure to increased cholesterol levels, the liver down regulates expression of LDL 
receptors on hepatocytes. Subsequently, clearance of LDL from the plasma 
decreases and circulating cholesterol increases until a new steady has been 
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established. This mechanism offers an explanation as to why obese individuals or 
individuals with naturally elevated cholesterol, may be less responsive to changes in 
dietary cholesterol. That is, people with elevated cholesterol, such as obese persons, 
tend to have higher rates of total body cholesterol synthesis and a larger pool of 
cholesterol circulating from the gut back to the liver51. Thus, a person with elevated 
cholesterol would have a lower response to dietary cholesterol because the amount 
taken in the with the diet would be small compared with the large amount already 
present in the enterohepatic cholesterol pool and it would, therefore, not contribute to 
further suppression of the LDL receptor20. In addition, there may be a link between 
obesity, insulin resistance, and diminished cholesterol absorption, however this has 
yet to be seen. Apart from genetic influence, the opposite can likely be said about 
non-obese, normolipidemic individuals, that dietary cholesterol is likely to more 
greatly effect cholesterol levels due to a lower circulating cholesterol pool.  
 
Lipoproteins 
Lipoproteins are particles that function to carry and transport TGs and 
cholesterol throughout the body. Essential to cell structure and metabolism, both TGs 
and cholesterol are hydrophobic molecules, which cannot move freely within the 
fluidic cardiovascular system. Thus, the body has engineered an eloquent system to 
transport these molecules. Lipoproteins are comprised of apolipoproteins, which 
function as ligands and in structural integrity of the molecule, a phospholipid bilayer 
(hydrophilic on the outside and hydrophobic on the inside), TGs, and cholesterol. The 
  12 
major apolipoproteins present and the relative contents of all the lipid components 
vary among different classes of lipoproteins. 
 Following the ingestion of a meal, the intestines packages consumed lipids 
into chylomicrons for transport around the body. Chylomicrons are primarily TG filled 
lipoproteins, which make their way towards the liver depositing fatty acids along the 
way in adipose, cardiac, and skeletal muscle tissues52,53. The liver produces VLDLs 
which function as the primary transport vehicle of TGs and free fatty acid delivery52. 
Removal of TGs from the VLDL core produces metabolic by-products known as 
LDLs. In most normal physiological conditions, these are the primary carries of 
circulating plasma cholesterol. All three of these lipoproteins, chylomicrons, VLDLs, 
and LDLs, carry apoB, in addition to other apolipoproteins. HDLs carry other 
apolipoproteins known as apoAI and apoAII. Nascent HDL particles are produced by 
the both liver and intestines. These newly formed HDL particles mature as they 
become enriched with additional other apolipoproteins and lipids through an 
exchange with chylomicrons and VLDLs52,53. Size and density of the various 
lipoproteins vary with chylomicrons being the largest and least dense, to the smallest 
and most dense HDL. Each lipoprotein class can further be broken down into a 
spectrum of distinct particles that vary in size, density, relative proportions of lipid and 
protein, as well as atherogenicity52. Figure 3 below illustrates the varying degree of 
subclasses, which have been discovered for each distinct lipoprotein class.  
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 Low-density lipoproteins (LDL) are the chief cholesterol-carrying lipoproteins in 
the human plasma and thus play a central role in atherogenesis. LDL-C has long 
been touted as “bad cholesterol”, since elevated levels have been associated with 
increased risk of coronary heart disease (CHD)16,17. Recently, the significance of 
LDL-C on its own as a marker of CVD risk has come into speculation within certain 
fields. Instead, LDL pattern type (A and B) has been receiving growing attention as a 
more accurate marker of CVD risk.  
Krause and Blanche122 where the first to divide the LDL gel electrophoresis 
profile into two distinct phenotypes, which they referred to as patterns A and B. 
Pattern A is distinguished by predominantly large-sized LDL, whereas pattern B is 
composed of a greater proportion of small, dese LDL particles. Results from their 
studies showed that ~25% of the sample population reported the pattern B 
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phenotype but that this was less frequent in women and younger subjects (<40 yrs). 
Not surprisingly, pattern B was associated with moderate elevation in plasma TGs 
and low levels of HDL-C54, a combination commonly termed the atherogenic 
lipoprotein phenotype. Patients with combined hyperlipidemia exhibit this atherogenic 
profile and are at an increased risk of CHD events regardless of their total LDL 
circulating mass55. 
 In a similar fashion as mentioned previously, plasma TGs have been shown to 
be the major determinant of the appearance of small, dense LDL particle’s, 
regardless of the method of analysis54,56,57. Packard et al.55 observed that the pattern 
B phenotype was infrequently seen in individuals with a plasma TG concentration 
less than 115 mg/dL, while above this level, small, dense LDL increased in 
propprotion to the plasma TG concentration.  
 The concern over small, dense LDL is that it has been shown to be more 
readily oxidized, at least in vitro, than its larger pattern A counterparts. Additionally, 
because of its reduced size it is likely to penetrate the aterial wall more easily, and 
we have been able to demonstrate that LDL from pattern B subjects have an 
enhanced affinity for arterial wall proteoglycan, thus prolonging its residence time in 
the subendothelial space124. All of these features contribute to the enhanced 
atherogenicity of this lipoprotein species. 
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Effects of Low Carbohydrate High Fat Diets on Blood Lipids 
One of the most consistent and predictable changes seen in those following a low 
carbohydrate diet is a reduction in circulating triacylglycerols (TGs)9,123. The primary 
mode of transport for TGs within the circulation is within very low-density lipoprotein 
particles (VLDLs). It is theorized that increased production or synthesis of TGs within 
the liver can increase the size and number of VLDLs synthesized and subsequently 
released into the circulation by the liver10. Thus, by restricting carbohydrates in the 
diet, lipogenesis within the liver, which occurs primarily from glucose derived sources 
(denovolipogenesis or DNL) from the standard American diet, is greatly reduced or 
entirely turned off. With DNL occurring at a much lower degree if it all, the liver has 
less TGs to package and traffic and needs to synthesize less VLDL particles.  
Serum cholesterol has long been of interest to both doctors and researchers. 
Consistent among dietary intervention studies that measured TC, LDL-C and HDL-C 
as outcome measures, is the large degree of individual variability10. This variability 
has been shown in a range of studies looking at high and low fat intake58 in the 
presence of carbohydrates, high and low cholesterol in the presence of fat and 
carbohydrates, and notably among low carbohydrate high fat intervention studies. It 
is thought that some individuals are sensitive to changes in dietary cholesterol and fat 
within the diet while others are insensitive. What’s more is that some believe varying 
cholesterol responses may result largely from test error and that replication of the 
same studies generates varying results59. The notion that cholesterol levels fluctuate 
based on diet and activity is largely overlooked on a day-to-day basis. Large 
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variability among cholesterol responses has been shown in those consuming various 
diets.  
Specifically, LCHFDs have been shown to reduce both fasting and 
postabsorptive TGs in both over weight/obese individuals as well as healthy, 
normolipidemic individuals10. This can largely be attributable to a reduction in 
carbohydrates as was previously described. The cholesterol response to LCHFDs as 
noted previously has been shown to be highly variable and is largely dependent on 
cholesterol levels prior to the adherence of a LCHFD. On average, it appears both 
TC and LDL-C increase following the consumption of a LCHFD in healthy 
normolidemic individuals but among those who have higher levels of cholesterol the 
response is different. HDL-C cholesterol has a more predictable response as it 
increases in nearly all individuals10.  
 
Effects of Low Carbohydrate High Fat Diets on Lipoproteins 
 
Proposed Physiological Mechanism 
A proposed theoretical mechanism for the effects of LCHF diets on circulating 
lipoproteins has been previously described by Volek et al.10 (Figure 2).  
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Figure 3: Paths up regulated during consumption of a LCHFD are represented by 
solid lines and those down regulated by dashed lines 
 
Fundamentally, adaptions that occur following a LCHFD result from a gluco-centric to 
lipid-centric shift in metabolism. Continued ingestion of a LCHFD initially increases 
circulating triacylglycerol (TAG)-rich chylomicrons, which are cleared rapidly by 
lipoprotein lipase (LPL) bound to the luminal surface of capillary endothelial cells both 
in skeletal muscle and adipose tissue56,104. Although not yet proven, it is likely 
LCHFD increase muscle LPL as the main source of fuel switches from glucose to 
fatty acids. Increased skeletal muscle LPL would thus facilitate TAG clearance. 
Reduced carbohydrate consumption effectively reduces glucose and insulin levels, 
indirectly decreasing adipocyte LPL and increasing hormone-sensitive lipase (HSL). 
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This metabolic hormonal shift promotes TAG hydrolysis and increases fatty acid (FA) 
rate and appearance throughout the body.  
 Increased skeletal muscle LPL is likely to result in LPL-mediated lipolysis of 
newly formed chylomicrons, resulting in a release of FA that is either taken up by the 
underlying tissue or escapes into the circulation. These circulating FAs are taken up 
by the liver and preferentially diverted away from esterification to TAG and toward 
mitochondrial oxidation to acetyl CoA. Accumulation for acetyl CoA exceeding the 
capacity for mitochondrial oxidation results in the formation of ketones. Decreased 
glucose availability for use by skeletal muscle shifts dependence towards fatty acids. 
Thus, any increase in FA delivery to skeletal muscle is balanced (utilized) by an 
increase in fat oxidation, as has been seen by postabsorptive respiratory exchange 
ratios close to or below 0.7 (unpublished data). 
 Reduced hepatic production of TAG, which normally occurs from excess fatty 
acids and glucose (Standard American diet), results in less VLDL synthesis and 
secretion into the circulation. Furthermore, LPL-mediated lipolysis of VLDL results in 
the transfer unesterified cholesterol, phospholipids (PL), and apolipoproteins to form 
mature HDL-C. Remaining remnant particles are either taken up by the liver or 
converted to LDL. Decreased circulating VLDL, particularly in the postprandial state, 
results in less cholesterol ester transfer protein (CETP)-mediated neutral lipid 
exchange with LDL-C. A reduction in hepatic lipase (HL) prevents larger LDL-C from 
being delipidated to smaller, dense (atherogenic) LDL, producing a predominance of 
larger LDL particles.
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Chapter 2 
Introduction 
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Low carbohydrate high fat diets (LCHFD) continue to show promise as a way 
to improve the cardiometabolic profile, not only in at-risk populations, but also within 
healthy individuals. Even so, long term safety and efficacy remain in question, as 
longitudinal LCHF studies are limited5-7 and contradict current health 
recommendations2,16. Variation in the cholesterol responses following adoption of a 
LCHFD8-13,60,61 warrant concern as elevated cholesterol levels have been associated 
with increased risk for cardiovascular diseases (CVD) and atherogenesis62. 
Advances in our understanding that atherogenesis is lipoprotein mediated, not 
cholesterol driven necessitate the need for more in depth comprehensive 
investigations be conducted.  
Cholesterol homeostasis (serum cholesterol levels) within the body reflects a 
balance between endogenous cholesterol synthesis (hepatic and extra-hepatic) and 
intestinal absorption (dietary and biliary cholesterol). Tight regulation of cholesterol 
balance helps prevent a net accumulation of cholesterol both within the tissues and 
circulation24,63 and disturbances in either input or output can increase atherogenic 
progression39,42,64. Considering some individuals consuming a LCHF diet present with 
increased cholesterol, whether or not this increase results from changes in 
absorption or synthesis has yet to be confirmed. To date, no previous studies have 
examined the response of a chronic low carbohydrate high fat diet on surrogate 
markers of cholesterol balance in healthy, fit men.  
Quantification of lipoprotein subfractions has become a well-recognized 
means of assessing atherogenic risk65,66 and is arguably better67. Distribution of 
lipoprotein subfractions towards a larger, more buoyant phenotype may help reduce 
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atherogenic risk, where as increased remnant lipoproteins (VLDL) and small, dense 
LDL particles may increase risk55. Smaller LDL particles are considered more 
atherogenic because of their ability to more easily penetrate the arterial wall, and 
their reduced binding affinity to the LDL receptor. This results in a prolonged 
circulating half-life and thus increased susceptibility to oxidation68-71. In addition, 
growing evidence suggests greater levels and size of triglyceride-rich lipoprotein 
(TRL) particles, primarily VLDL remnants, are likely to contribute to atherogenic 
risk72-74 through eventual conversion to small LDL particles68,75. Finally, it appears the 
protective effects of HDL may be more largely attributable to large HDL particle 
subfractions76. 
Lipoprotein subfractions and surrogate markers of cholesterol balance provide 
viable measures for evaluating the impact LCHFD have on overall long-term 
cardiometabolic health. Such measures provide a far more detailed analysis of 
metabolic risk than current clinical biomarkers (fasting total cholesterol, LDL 
cholesterol, HDL cholesterol and triacylglycerides). Thus, the primary purpose of this 
study was to compare the effects of a chronic (>6 months) LCHF diet to that of a high 
carbohydrate (HC) diet on markers of lipoprotein metabolism and cholesterol 
absorption and synthesis. We first hypothesized that increased consumption of 
cholesterol among men following a chronic LCHF diet would not demonstrate a 
significant shift in fractional cholesterol balance compared with those consuming a 
chronic HC diet. Secondly, we hypothesized that a chronic LCHF diet would produce 
a less atherogenic lipoprotein profile when compared to a HC diet. Despite increased 
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circulating cholesterol levels among individuals consuming a chronic LCHF diet, we 
propose that this cholesterol is carried in larger, less atherogenic lipoproteins. 
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Experimental Approach 
The following data is an extension of a larger cross-sectional investigation {Volek et 
al 2015 pending} that reported on metabolic responses in two groups of elite ultra-
marathoners habitually consuming either a LC or HC diet. The purpose of the current 
analysis was to more closely examine the effect of diet on markers of lipoprotein 
metabolism and surrogate markers of cholesterol balance. 
 
Participants 
Twenty highly trained male ultra-endurance runners consuming a LC (n=10) or a HC 
(n=10) diet 21-45 years of age were selected for participation.  Athletes competed in 
sanctioned running events ≥50 km and/or triathlons of at least half iron man distance 
(113 km) and where in the top 10% of finalists.  Athletes were carefully matched for 
age, physical characteristics, primary competition distance, and competition times.  
With one exception, all athletes lived in the United States and traveled via plane to 
our laboratory for two days of testing. Interested athletes completed questionnaires to 
assess their medical, diet, training, and running competition history. At least one 
phone call was scheduled to review this information and determine eligibility and 
availability. Diet information was entered into commercial nutrient analysis software 
(Nutritionist ProTM, Axxya Systems, Stafford, TX).  Subjects consuming a LC diet, 
defined as <20%en from carbohydrate and >60%en from fat, consistently for at least 
6 months were eligible for the LC group. Subjects consistently consuming >55%en 
from carbohydrate were considered for the HC group.  Athletes were excluded if they 
did not consume the appropriate diet for the allotted amount of time or had any health 
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issues, including, but not limited to diabetes, heart disease, kidney, liver, or other 
metabolic or endocrine dysfunction, current injury, anti-inflammatory medication use, 
anabolic drug use, or prone to excessive bleeding. Subjects were informed of the 
purpose and possible risks of the investigation prior to signing an informed consent 
document approved by the Institutional Review Board. 
 
Measurements 
Full methods have been described previously {Volek et al 2015 pending}. Briefly, 
athletes arrived at the laboratory at 0600 after a 10 hr overnight fast and were asked 
to restrict caffeine, over the counter medications, and alcohol. The night prior and 
morning before testing, subjects were encouraged to liberally consume water to 
ensure hydration. A small urine sample was provided to assess specific gravity 
(Model A300CL, Spartan, Japan) as a measure of hydration (all subjects had a USG 
>1.025). Body composition was determined by dual-energy X-ray absorptiometry 
(DXA) (Prodigy, Lunar Corporation, Madison, WI). Height was measured to the 
nearest 0.1 cm and total body weight was recorded to the nearest 0.1 kg on a digital 
scale (OHAUS Corp., Fordham Park, NJ).  
 
Blood Collection and Analysis 
All blood samples were obtained with a 21G butterfly needle from an antecubital vein 
of the subject. After resting quietly for 15 min in a supine position, blood was 
collected into ethylenediaminetetraacetic acid (EDTA) and serum separator 
vacutainer tubes (Vacuette, Greiner Bio-one North America, Inc., Monroe NC). EDTA 
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tubes were immediately spun while serum tubes remained at room temperature for 
15 min prior to centrifugation to allow clotting to occur. Whole blood was centrifuged 
(1500 x g for 15 min at 4°C), promptly aliquoted into cryostorage tubes, snap frozen 
with liquid nitrogen, and stored at -80°C for later analysis. One 10mL serum tube was 
immediately sent on ice to a certified medical laboratory (Quest Diagnostics, 
Wallingford, CT) for determination of glucose and other blood analytes using 
automated enzymatic procedures (Olympus America Inc., Melville, NY). 
Frozen samples were thawed only once before analysis of all variables. Baseline 
EDTA plasma was analyzed for total cholesterol, HDL cholesterol, and triglycerides 
using enzymatic methods on an automated analyzer (Cobas C 111, Roche 
Diagnostics, Indianapolis, IN). Concentrations of total and LDL cholesterol were also 
measured using standard enzymatic methods77,78.  
Analysis of lipoprotein (high, low, and very low density lipoproteins [HDL, LDL, 
and VLDL] particle size and number was conducted by Liposciences Inc. (Raleigh, 
NC) using hydrogen nuclear magnetic resonance (H-NMR) on a 400 MHz NMR 
analyzer (Bruker BioSpin Corp, Billerica, MA) as previously described by Jeyarajah 
and colleagues79,80. Lipoprotein subclasses were grouped based on particle 
diameters: large VLDL (>60 nm), medium VLDL (35–60 nm), small VLDL (27–35 
nm), intermediate- density lipoproteins [IDL] (23–27 nm), large LDL (21.2–23 nm), 
medium LDL (19.8–21.2 nm), small LDL (18–19.8 nm), large HDL (8.8–13 nm), 
medium HDL (8.2–8.8 nm), and small HDL (7.3–8.2 nm). Lipoprotein insulin 
resistance index (LP-IR) was calculated by Liposciences Inc. (Raleigh, NC) combing 
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six lipoprotein measures (VLDL, LDL, and HDL size, large VLDL-P, small LDL-P, and 
large HDL-P) into a single algorithm81. 
Concentrations of noncholesterol sterol precursors (lathosterol, desmosterol, 
cholestanol, sitosterol, and campesterol) were also quantified by Boston Heart 
Diagnostics using a gas chromatography mass-spectrometry (GCMS) method similar 
to that previously described82. To eliminate the effect of different cholesterol levels, 
absolute values were standardized and expressed in terms of 102×mol/mmol of 
cholesterol (ratios to cholesterol values). 
 
Statistical Analysis 
Means and standard deviation were calculated for all variables using conventional 
methods. Differences between groups for demographic characteristics, diet, 
lipoprotein subfractions, and surrogate markers of cholesterol balance were 
assessed using independent samples t-tests. Normality testing was performed using 
the Shapiro-Wilks test and non-normal data were analyzed with the Mann-Whitney U 
test. Normal data with significant variance was analyzed using the Welches unequal 
variance t-test. Relationships between variables were examined using Pearson’s 
product-moment correlation coefficients. The level of significance was set at p ≤ 0.05. 
All statistical analyses were preformed using Prism Graphpad (Software Version 6.0, 
La Jolla, CA). 
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Subject Characteristics and Diet  
There were no significant differences between groups in physical characteristics or 
aerobic capacity (Table 1). Two athletes in each group were triathletes and all others 
competed in events largely ranging from 80 to 161 km (50 to 100 miles).   
Primary differences between groups were among diet (Table 2). Total dietary caloric 
intake and total macronutrient grams consumed (protein + fat + carbohydrates) did 
not differ between groups (Table 2). Total grams of carbohydrate (p < 0.0001) and fat 
(p < 0.0001) consumed were significantly different between groups for both the 
habitual and pre-testing diets (Table 2, 3 and Figure 1). Individuals in the LC group 
derived a majority of their energy from fat (70%), predominantly in the forms of 
saturated and monounsaturated fatty acids. Only ~10% of energy intake was from 
carbohydrate sources.  Conversely, individuals in the HC group consumed over half 
their energy in the form of carbohydrates (57%).  Protein was not significantly 
different between groups. Notably, dietary cholesterol intake was significantly greater 
(p < 0.003) in the LC group (844 mg/day) compared with the HC group (291 mg/day) 
(Table 2). The average duration on a LC diet ranged from 9 to 36 months. 
 
Plasma Lipids 
Men consuming a LCHF diet had significantly greater (p < 0.0001) serum total 
cholesterol (64.6%), LDL-C (p < 0.0001) (83.1%), and HDL-C (p < 0.0007) (52.9%) 
compared to the HC group (Table 4, Figure 2). This did not however adversely affect 
the HDL-C to triglyceride ratio. Serum triglycerides were not different between 
groups, although LCHF men had a significantly (p < 0.0113) lower TG/HDL ratio.  
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Fractional Cholesterol Balance and Noncholesterol Sterols 
No significant differences existed between groups following the calculation of 
fractional cholesterol balance [Fractional Cholesterol Balance = (lathosterol × 0.8 + 
desmosterol × 0.2)/(beta-sitosterol × 0.5 + campesterol × 0.5)]. Absolute and 
normalized sterol levels are presented in (Table 8). Non-cholesterol sterols are 
transported in plasma by lipoproteins and to correct for variations in lipoprotein levels, 
sterol concentrations are frequently expressed relative to the concentration of total 
cholesterol (μmol/mmol of cholesterol). Absolute levels of each measured sterol were 
greater in the LCHFD group with desmosterol (p < 0.0003) and cholestanol (p < 
0.0087) being significant. When normalized to cholesterol, all sterol values apart from 
desmosterol where greater in the HCD group. Normalized values of lathosterol (p < 
0.0158), desmosterol (p < 0.0455), cholestanol (p < 0.0026), and campesterol (p < 
0.0185) were significantly different between groups.      
 
Noncholesterol Sterols Related to Serum Cholesterol 
The serum concentrations of all noncholesterol sterols were significantly correlated 
with HDL cholesterol (Table 9). In addition, all sterols but campesterol where 
significantly correlated with total and LDL cholesterol. When values were normalized 
to cholesterol, noncholesterol sterol levels were no longer correlated with total 
cholesterol and only desmosterol and campesterol remained significantly correlated 
with LDL cholesterol. Cholestanol was the only sterol to remain correlated with HDL 
cholesterol.  
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VLDL, LDL, and HDL Particle Size and Quantity and LP-IR 
VLDL particle size, but not total particle number, was significantly lower (p < 0.0022) 
(-14.3%) in men who consumed a LCHF diet (Table 5). Of the varying particle sizes, 
only large VLDL particles were significantly (p < 0.0062) lower (-126.8%) in the LCHF 
group compared to the HC. Both groups presented with large pattern A particles 
(Table 6). Those following a LCHF diet had significantly larger (p < 0.0102) LDL 
particles.  Total LDL particle number was significantly higher (p < 0.0021) by 52.7% 
in the LCHF group; however, this significant difference was caused by a 124.8% 
increase (p < 0.0001) in the large and a 140.2% increase (p < 0.0021) in the 
intermediate particles. Although not statistically significant (p < 0.1013) due to large 
variation within the HC group and outliers in the LCHF group, median small particle 
size (most atherogenic), was 126% greater in the HC group. Upon removal of two 
LCHF outliers, however, the difference between groups becomes significant (p < 
0.083) and the percent change more than doubles (264.8%). Men consuming a 
LCHF diet had HDL particles significantly (p < 0.0053) larger (7.3%) than those 
consuming a HC diet (Table 7). Total HDL particles were not different between 
groups; however, men in the LCHF group had significantly greater (p < 0.0013) larger 
particles (82.6%), and significantly (p < 0.0038) less (-56%) medium particles 
compared to the HC group. Small HDL particles were not different between groups. 
The lipoprotein insulin resistance index (LP-IR) was significantly lower in the LCHF 
group by 360% (p < 0.0001) revealing a significantly reduced predictive risk for 
insulin resistance (Table 4, Figure 3).  
  32 
 
 
 
Chapter 5 
Discussion 
 
 
 
 
 
 
 
 
 
  33 
 In the present study, we sought to compare the lipoprotein and cholesterol 
responses in healthy, active, normal-weight men who were chronically adapted to 
either a low carbohydrate high fat diet (LCHFD) or a high carbohydrate diet (HCD). 
LCHFDs continue to remain controversial in regards to their impact on health and 
long-term safety83, and while few long-term studies (> 6 months) have sought to 
validate LCHFD in this realm, only cholesterol mass responses in obese participants 
have been measured4-7. Thus to date, this is the first study to measure surrogate 
markers of cholesterol synthesis and absorption as well as the lipoprotein profile in 
healthy, active, normal-weight men adapted to a LCHFD (> 6 months).  
LCHFDs have received criticism for their potential to increase circulating 
serum cholesterol mass. Previously conducted short-term LCHFD studies in healthy, 
normolipidemic subjects corroborate these findings8-13, however, frequently 
disregarded is the notion that individual cholesterol responses following a LCHFD 
can be highly variable13 and are elevated as a result of significant increases in HDL-
C. Despite significant increases in dietary and circulating cholesterol, we proposed 
men following a long-term (> 6 month) LCHFD would not demonstrate altered 
fractional cholesterol balance and would exhibit favorable changes in circulating 
lipoproteins subfractions. 
 
 
 
Plasma Lipids 
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Mean dietary cholesterol intake among men following a LCHFD was 190% 
greater (553 mg/d), or more than triple those consuming a HCD. Based on previously 
conducted LCHF studies in healthy normolipidemic men8-13, elevated cholesterol in 
our LCHF group was not unexpected; TC, LDL-C, and HDL-C were significantly 
higher by 64.6%, 83.1%, and 52.9% respectively. Correspondingly, we found dietary 
cholesterol intake demonstrated significant correlations with cholesterol measures 
(TC: r = 0.75, p < 0.0001; LDL-C: r = 0.71, p < 0.0005; HDL-C: r = 0.54, p < 0.0135). 
Elevated cholesterol in the LCHF group suggests a potential hyper responsiveness to 
dietary cholesterol, however this was not possible to determine given the cross-
sectional nature of the study. Regardless, hyper-absorption in response to increased 
dietary cholesterol consumption is unlikely to explain such a dramatic elevation in 
cholesterol levels in men as fit as ours84.    
Consistent with variable cholesterol responses, men in the LCHFD group 
displayed a greater range of TC values (LCHF = 162, HC = 65) than men in the HC 
group. Cholesterol feeding has previously been shown to produce large 
interindividual variability in circulating cholesterol19. Furthermore, leanness of the 
subjects may have contributed to a more dramatic response18,85. Such disparity in the 
responsiveness of blood cholesterol following the adoption of a LCHFD is thought to 
occur largely from individual variations in hormonal factors, obesity, and genetic 
predisposition19, although this has yet to be fully determined. Both groups had 
extremely favorable HDL-C levels (> 40mg/dL), a trait likened to a the elite fitness 
level of our subjects86.  
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High HDL-C levels among athletes is not uncommon87. It has been well 
established that endurance training increases HDL-C cholesterol88,89 and promotes 
enhanced cholesterol efflux90. Various physiological mechanisms have been 
attributed to this adaptation including increased LPL activity91, decreased cholesterol 
ester transfer protein (CETP)92, and increased expression of ABCA1 transporters 
necessary for HDL genesis93. Even more notable were the significantly greater HDL-
C levels among men in the LCHF group. To our knowledge, further increases in HDL-
C beyond those seen with exercise can only be attributed to differences in diet as TG 
levels were not significantly different between groups. Short term LCHFDs 
consistently show positive changes in circulating HDL-C levels among normal 
weight11,60 and overweight individuals94-96. Studies evaluating the long-term (> 6 mo) 
HDL-C response in healthy men has yet to be conducted, however those carried out 
in obese patients have show increases in HDL-C5-7. Considering this fact, it is not 
unreasonable to expect significantly elevated HDL-C following chronic LCHFD in 
healthy fit men.  
Surrogate Markers of Cholesterol Synthesis and Absorption 
Plasma non-cholesterol sterols can be measured to assess cholesterol 
homeostasis and correlate strongly with absolute cholesterol synthesis and 
absorption44,97,98. With varied cholesterol responses previously reported in men 
consuming LCHFDs8-13, we sought to assess whether a chronic ( > 6 months) free-
living LCHFD shifts cholesterol homeostasis in favor of synthesis or absorption. The 
ratio of cholesterol synthesis markers (lathosterol and desmosterol) to absorption 
markers (beta-sitosterol and campesterol) can be used to calculate fractional 
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cholesterol balance. A reduced ratio (< 0.5) is indicative of greater serum phytosterol 
concentrations and increased cholesterol absorption at the gut lumen where as 
raised fractional values ( > 1.1) are representative of elevated cholesterol precursors 
and imply increased synthesis of cholesterol. To date, no previous long-term LCHFD 
studies have utilized these surrogate markers to assess cholesterol balance in 
healthy, fit, individuals.  
Quite remarkably, calculated mean fractional cholesterol balance was similar 
between groups (LCHF = 0.66, HC = 0.60) and was not indicative of increased 
absorption or synthesis. Given that men in the LCHFD group consumed significantly 
greater levels of dietary cholesterol and maintained significantly greater levels of 
circulating cholesterol, this finding was noteworthy. Extrapolation of these findings 
may suggest men who follow a chronic LCHFD expand their endogenous cholesterol 
pool before establishing a new circulating homeostatic level18,99. Similar to cholesterol 
levels, we found surrogate markers in both groups to be greatly variable, in line with 
other findings32, and further substantiating an individualized, likely genetic, response 
to diet.  
Noncholesterol sterols are novel biomarkers not yet endorsed by international 
guidelines, but can be useful in determining clinical approaches for elevated 
cholesterol (hypercholesterolemia)29. Although men following a LCHFD were 
hypercholesterolemic (TC > 200mg/dL), all normalized sterol levels except 
desmosterol were greater in the HC group. Considering current recommended 
ranges for normalized sterol levels have been established using data from patients 
consuming a traditional American diet, normalizing noncholesterol sterols many not 
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be appropriate for assessment of over absorption and synthesis in LCHF adapted 
individuals. Greater absolute sterol values in the LCHF group were not surprising 
given the elevated cholesterol levels in those men. Significantly greater absolute 
desmosterol levels in the LCHF men would seem to imply greater production of 
cholesterol, however, the pathway through which desmosterol forms cholesterol is 
thought to contribute far less to overall synthesis than the lathosterol, which was not 
significantly different between groups. Apart from campesterol, absolute values of 
noncholesterol sterols showed significant positive corrections with total, LDL, and 
HDL cholesterol supporting the relationship between elevated sterol biomarkers and 
circulating cholesterol levels. We are the first to measure noncholesterol sterols in 
healthy, fit men, making it difficult to fully elucidate our findings. The effect exercise 
training has on surrogate cholesterol markers remains to be seen and further 
research is necessary to understand how noncholesterol sterols levels respond to 
long term LCHFDs.  
 
Lipoprotein Particle Distribution, Size, and LP-IR 
NMR analysis revealed favorable, pattern A, lipoprotein profiles in both 
groups. Considering the elite fitness level among men recruited for this study, we 
acknowledge that adaptation to endurance exercise influences lipoprotein particle 
distribution independent of diet86,88. Nonetheless, we found a LCHFD resulted in an 
even more favorable lipoprotein profile (less atherogenic) compared to consuming a 
HCD. Though pattern type (A or B) is influenced by genetic inheritance54, dietary 
change can also alter particle distribution, particularly atherogenic LDL subclasses56.  
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In support of previous literature11,14,100, reduced carbohydrate consumption 
among men following a LCHFD (< 100 g/day), in combination with less circulating 
TGs (-10.4%) and VLDLs (-27.9%), is likely the primary contributing factor towards an 
atheroprotective shift in lipoprotein metabolism (less atherogenic LDL particles [LDL-
P] and greater atheroprotective HDL particles [HDL-P]). Still, cholesterol feeding with 
eggs has been shown to favorably alter LDL subclasses84. Dietary carbohydrate 
reduction has consistently been shown to result in a significant decrease in both 
fasting and postprandial TGs1,11,14,100. Due to the natural metabolism of TG rich 
VLDLs to LDLs, a reduction in TGs results in less VLDL synthesis by the liver and 
therefore a direct reduction in circulating LDL particles10. In addition, reduced 
circulating TGs decrease cholesterol-TG transfer between TG rich-VLDLs and LDL 
via CETP, allowing for HDL and LDL to carry a greater capacity of cholesterol, 
resulting in larger, more buoyant lipoproteins101.  
 Differences in TGs and VLDL subfractions among groups is likely attributable to a 
combination of reduced carbohydrate consumption, reduced VLDL production rate, 
shown to increase on a high carbohydrate diet102, and an increase in TG removal 
given high-fat diets ( > 45% total energy) promote increased postheparin plasma and 
skeletal muscle LPL activity in humans56,103,104. Reduced TGs are likely responsible 
for a significant 14.3% reduction in mean VLDL particle (VLDL-P) size, reduced total 
number, and decreased size of VLDL-P subfractions. Significant positive correlations 
between circulating TGs and VLDL particle count and subfractional size support this 
assessment (Total VLDL-P: r = 0.94, p < 0.0001; Large VLDL-P: r = 0.66, p < 0.0016; 
Medium VLDL-P: r = 0.88, p < 0.001; Small VLDL-P: r = 0.64, p < 0.0026). Although 
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LCHF adapted men had less total, large, medium, and small VLDL-P compared to 
men in the HCD group, only large VLDL-P were found to be significantly lower as a 
result of wide particle variation among participants. 
Reduced VLDL-P size among men adapted to LCHFDs affected LDL particle 
size. Smaller denser LDL particles evolve from elevated levels of TGs and thus larger 
VLDL particles22,68,105,106, primarily as a result of hepatic lipase101. This was evident in 
the men adapted to a LCHFD as supported by the strong negative relationship 
between the two measures (r = -0.70, p < 0.006). Convincingly, mean LDL particle 
size was significantly greater in the LCHF group compared to the HCD group. Total 
LDL particle count was 52.7% greater among men consuming a LCHFD, however, 
the distribution of LDL particles was dominated by large and intermediate particles 
(88.2% of total particles) while in the HC group, large and intermediate particles 
made up 59.3% of total LDL particles.  
Of considerable importance are the findings related to small LDL-P, those 
attributed with an increased risk of CVD54,57,107. Two men within the LCHF group 
prevented small LDL particles from being statistically significant between groups. 
Regardless, small LDL particles comprised 40.7% of total particles in men who 
consumed a HCD compared to only 11.8% in men on a LCHFD. As a whole, HC men 
had 126% more small LDL particles than those in the LCHF group. Considering LDL-
C levels in the LCHF group were nearly double those in the HC groups (161.3 vs 
88.1 mg/dL), these findings suggest elevated LDL-C in men consuming a chronic 
LCHFD does not contribute to the development of atherogenic small LDL-P and that 
elevated LDL-C may not be a good predictor of atherogenesis in those who follow a 
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LCHFD. These findings support previous LCHF studies which demonstrate restricting 
dietary carbohydrate increases mean LDL particle size, reduces small LDL-P, and 
subsequently shifts particle pattern11,14,60,94,108-112. 
Carbohydrate restriction, reduced TGs, and increased dietary cholesterol can 
similarly be attributed to the positive shift in HDL lipoproteins. Mean HDL size was 
significantly larger in the LCHFD group, suggesting a reduced uptake of HDL 
particles by the liver and thus increased circulating HDL-C concentrations111,112. 
Although not statistically different, total HDL-P were greater in the LCHF group. Large 
atheroprotective HDL particles76,113 were significantly greater in the LCHF group 
accounting for 39.6% of total particles, in contrast to 23.9% in men consuming a 
HCD. Although not measured in the current study, cholesterol ester transferase likely 
plays a role increasing large HDL particles in the LCHF group114. Interestingly, men 
on a HCD had a 56% greater number of medium HDL particles compared to the 
LCHF group. Because men following a LCHFD had reduced circulating TGs, it is 
probable that neutral lipid exchange between VLDL and HDL lipoproteins was 
reduced, resulting in the formation of fewer TG-rich HDL particles. If HDL particles 
contained less TGs, it would reduce their susceptibility to remodeling by hepatic 
lipase, yielding fewer small HDL particles14. 
The lipoprotein insulin resistance index (LP-IR) is an effective tool to 
summarize the NMR results. The LP-IR index is an algorithmic system which gives 
numeric weight to six parameters of the NMR lipoprotein profile test associated with 
insulin resistance115-117 (VLDL, LDL, and HDL size, large VLDL-P, small LDL-P, and 
large HDL-P). The final LP-IR score is calculated by summing the six NMR parameter 
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scores81. Shalaurova et al.81 recently demonstrated the value of the index in 
predicting insulin resistance. Although both groups in the present study were 
comprised of healthy fit males who’s mean LP-IR scores fell just at or below the 25th 
percentile (< 25), those following a LCHFD showed an astoundingly lower (-360%) 
LP-IR score. Knowing that insulin resistance precedes the development of obesity, 
metabolic syndrome, and type 2 diabetes mellitus, such a significantly lower LP-IR 
score in men consuming a LCHFD, even among healthy fit individuals, provides 
further evidence for the therapeutic potential of LCHFDs in treating these metabolic 
abnormalities.  
Despite significantly greater consumption of dietary cholesterol by men 
consuming a chronic LCHFD, surrogate markers of cholesterol synthesis and 
absorption did not reveal a direct cause (increased synthesis or absorption) for 
elevated serum cholesterol (TC, LDL-C, and HDL-C) within the LCHF group. 
Although speculative, individuals who adopt a LCHFD may experience an expansion 
of their endogenous cholesterol pool during the adaptation phase of the diet, after 
which they maintain greater circulating cholesterol levels but no increased risk for 
CVD. Increased cholesterol consumption, elevated cholesterol levels, and low rates 
of heart disease in indigenous Inuit populations suggest this may be true118-121. In 
further support of this theory, we found that regardless of an increase in total and 
LDL cholesterol within the LCHFD group, these men had more favorable lipoprotein 
profiles in regards to CVD risk than those consuming a HCD, notably less small LDL 
particles. Current evidence suggests CVD is lipoprotein-mediated, leaving 
measurements of circulating cholesterol nearly obsolete in their efficacy for predicting 
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heart disease. Additional research is necessary to fully determine if elevated LDL 
cholesterol in LCHF individuals presents an increased risk for CVD.  
Limitations of this study include small sample size, cross-sectional design, 
surrogate measures of cholesterol balance rather than absolute cholesterol turnover, 
and lack of measured variables such as enzymes important in lipoprotein metabolism 
and markers of LDL oxidation. These data should be regarded as pilot data requiring 
future, more in-depth studies be conducted to fully determine the meaning of these 
data. Increased cholesterol did not occur as a result of over absorption or synthesis 
as measured by surrogate markers and suggests the body may maintain a new 
homeostatic set point upon adaptation to a LCHFD. Our findings support the notion 
that long-term LCHFD can increase circulating cholesterol mass but in so doing, shift 
lipoprotein size and particle distribution towards a more favorable less atherogenic 
profile.  
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Tables & Figures 
Table 1. Baseline Subject Demographics1 
 High Carb Low Carb 
Age (yr) 32.9 ± 6.0 34.1 ± 7.1 
Height (cm) 173.9 ± 5.3 175.7 ± 6.5 
Body Mass (kg) 66.5 ± 6.8 68.8 ± 8.2 
Body Fat (%)2 9.6 ± 4.3 7.8 ± 2.4 
Lean Mass (kg)2 57.3 ± 5.0 60.9 ± 7.1 
Fat Mass (g) 6.5 ± 3.6 5.46 ± 1.8 
VO2max (mL/kgmin) 64.6 ± 6.1 64.6 ± 4.3 
1Values are mean ± SD (n=10). 
2Determined by dual-energy X-ray absorptiometry. 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Daily macronutrient breakdown for habitual diet1 
   
Habitual Diet2 High Carb Low Carb 
Energy (kcal/day) 3044 ± 604 2884 ± 814 
Protein (g/day) 117 ± 39 139 ± 32 
Protein (%en) 14.9 ± 3.9 19.4 ± 2.4 
Protein (g/kg) 1.7 ± 0.4 2.1 ± 0.6 
Carbohydrates (g/day) 442 ± 116 82 ± 62**** 
Carbohydrates (%en) 56.5 ± 10.2 10.4 ± 4.9**** 
Fat (g/day) 94 ± 33 226 ± 66**** 
Fat (%en) 26.7 ± 7.5 69.5 ± 6.0**** 
Saturated fat (g/day) 22 ± 10 86 ± 22**** 
Monounsaturated fat (g/day) 32 ± 16 82 ± 42*** 
Polyunsaturated fat (g/day) 17 ± 9 28 ± 17 
Alcohol (%en) 1.8 ± 2.7 0.7 ± 1.4 
Cholesterol (mg/day) 291 ± 256 844 ± 351** 
Fiber (g/day) 48 ± 15 23 ± 17** 
   
1Values are mean ± SD (n=10). 
23-Day 24-Hr food record including one weekend day. 
Asterisks indicate significant difference between groups: 
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 
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Table 3. Daily macronutrient breakdown for pre-testing diet1 
   
Pre-testing Diet2 High Carb Low Carb 
Energy (kcal/day) 2856 ± 846 2572 ± 597 
Protein (g/day) 118 ± 41 148 ± 34 
Protein (%en) 16.4 ± 3.5 23.2 ± 5.7 
Protein (g/kg) 1.7 ± 0.4 2.2 ± 0.7 
Carbohydrates (g/day) 371 ± 107 64 ± 27**** 
Carbohydrates (%en) 50.9 ± 5.0 10.4 ± 5.4**** 
Fat (g/day) 95 ± 26 195 ± 65** 
Fat (%en) 29.5 ± 2.8 66.0 ± 8.8**** 
Saturated fat (g/day) 25 ± 9 79 ± 37** 
Monounsaturated fat (g/day) 29 ± 17 69 ± 29* 
Polyunsaturated fat (g/day) 16 ± 3 19 ± 7 
Alcohol (%en) 3.2 ± 4.2 0.3 ± 0.7* 
Cholesterol (mg/day) 302 ± 364 883 ± 320** 
Fiber (g/day) 37 ± 13 20 ± 12* 
   
1Values are mean ± SD (n=10). 
22-Day 24-Hr food record prior to test day.  
Asterisks indicate significant difference between groups: 
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 
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Figure 1: No statistical differences between Habitual Diet and Pre-test Day 
 
 
 
 
Dietary Macronutrient Distrubution
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Table 4. Serum Cholesterol and Lipids 1 
Variable High Carb Low Carb 
Total Cholesterol (mg/dL) 168.7 ± 24.4 277.7 ± 50.58**** 
LDL Cholesterol (mg/dL) 88.1 ± 13.68 161.3 ± 37.38**** 
HDL Cholesterol (mg/dL) 63.9 ± 17.99 102.3 ± 26.21** 
Total Cholesterol/HDL Cholesterol  2.74 ± 0.47 2.81 ± 0.53 
Triglycerides (mg/dL) 70.0 ± 25.09 63.4 ± 17.26 
Triglycerides/HDL Cholesterol 1.15 ± 0.49 0.67 ± 0.23* 
Lipoprotein Insulin Resistance Index2 26.7 ± 10.47 5.8 ± 5.75*** 
1Values are mean ± SD (n=10). 
2Combined algorithm of six lipoprotein measures.  
To convert to SI units, multiply total cholesterol, LDL-C, HDL-C (mg/dL) × 0.0256 = mmol/L; 
multiply triglycerides (mg/dL) × 0.0113 = mmol/L. 
Asterisks indicate significant difference between groups:  
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 
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Figure 2: Total, LDL, and HDL cholesterol group spread values. 
Values are mean ± SD (n=10). 
Asterisks indicate significant difference between groups: 
**P < 0.01; ***P < 0.001; ****P < 0.000
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Table 6. LDL size and concentration of total LDL particles and LDL subfractions1 
Variable High Carb Low Carb 
LDL Particle Size (nm) 20.99 ± 0.35 21.47 ± 0.34** 
Total LDL Particles (nmol/L) 892.8 ± 195.8 1363 ± 343.1** 
Large LDL Particles (nmol/L) 456.4 ± 101.0 1026 ± 258.9**** 
Intermediate LDL Particles (nmol/L) 73.4 ± 76.92 176.3 ± 63.87** 
Small LDL Particles (nmol/L) 363.0 ± 245.2 160.6 ± 134.8 
1Values are mean ± SD (n=10). 
Asterisks indicate significant difference between groups: 
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 
 
 
Table 7. HDL size and concentration of total HDL particles and HDL subfractions1 
Variable High Carb Low Carb 
HDL Size (nm) 9.51 ± 0.47 10.2 ± 0.47** 
Total HDL Particles (nmol/L) 33.96 ± 5.35 37.38 ± 4.43 
Large HDL Particles (nmol/L) 8.1 ± 3.41 14.79 ± 4.41** 
Medium HDL Particles (nmol/L) 12.9 ± 3.06 8.27 ± 3.18** 
Small HDL Particles (nmol/L) 12.96 ± 5.54 14.31 ± 5.19 
1Values are mean ± SD (n=10). 
Asterisks indicate significant difference between groups: 
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 
 
Table 5. VLDL size and concentration of total VLDL particles and VLDL subfractions1 
Variable High Carb Low Carb 
VLDL Particle Size (nm) 43.65 ± 1.72 38.2 ± 4.09** 
Total VLDL Particles (nmol/L) 48.10 ± 25.47 37.61 ± 5.90 
Large VLDL Particles (nmol/L) 1.27 ± 0.70 0.56 ± 0.09* 
Medium VLDL Particles (nmol/L) 13.55 ± 15.36 4.12 ± 3.70 
Small VLDL Particles (nmol/L) 33.26 ± 14.29 32.94 ± 18.41 
1Values are mean ± SD (n=10). 
Asterisks indicate significant difference between groups: 
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 
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Figure 3: Lipoprotein Insulin Resistance Index Measures. 
Values are mean ± SD (n=10). 
Asterisks indicate significant difference between groups: 
**P < 0.01
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Table 8. Fractional cholesterol balance and non-cholesterol sterols 1 
 High Carb Low Carb 
Fractional Cholesterol Balance2 0.60 ± 0.16 0.66 ± 0.22 
 
 
Absolute (mg/L) 
Desmosterol 1.42 ± 0.24 2.82 ± 0.80*** 
Lathosterol 1.84 ± 0.55 2.23 ± 0.61 
Campesterol 3.5 ± 1.46 3.86 ± 1.37 
Sitosterol 3.07 ± 1.03 4.34 ± 1.75 
Cholestanol 2.23 ± 0.44 2.8 ± 0.43** 
  
Normalized (102 x μmol/mmol of TC) 
Desmosterol 84.8 ± 11.55 101.9 ± 22.35* 
Lathosterol 109.4 ± 30.67 79.6 ± 14.41* 
Campesterol 195.0 ± 59.04 134.7 ± 43.98* 
Sitosterol 167.7 ± 44.65 145.8 ± 55.03 
Cholestanol 132.3 ± 24.44 101.5 ± 13.4** 
1Values are mean ± SD (n=10). 
2Calculated with normalized values 
Asterisks indicate significant difference between groups: 
*P < 0.05; **P < 0.01; ***P < 0.001 
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Table 9. Correlations of serum noncholesterol sterols with serum total and 
lipoprotein cholesterol levels among healthy, fit men (n=20) 
Sterols 
Serum Cholesterol (mg/dL) 
Total Cholesterol LDL Cholesterol HDL Cholesterol 
 Absolute (mg/L) 
Desmosterol 0.8851**** 0.9169**** 0.5972** 
Lathosterol 0.6231** 0.5900** 0.5413* 
Campesterol 0.4327 0.2528 0.5321* 
Sitosterol 0.6179** 0.5042* 0.6268** 
Cholestanol 0.7141*** 0.6106** 0.6162** 
 
Normalized (102 x μmol/mmol of TC) 
Desmosterol 0.3963 0.5262* 0.07971 
Lathosterol -0.4269 -0.3877 -0.3359 
Campesterol -0.3318 -0.4561* -0.1279 
Sitosterol -0.1371 -0.2114 0.005034 
Cholestanol -0.6654 -0.0348 -0.5312* 
Both groups (n=20), Low Carb (n=10), High Carb (n=10) 
Asterisks indicate significant difference between groups: 
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. 
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